Share This Page
Drug Price Trends for NDC 70512-0106
✉ Email this page to a colleague
Average Pharmacy Cost for 70512-0106
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DICLOFENAC SODIUM 1% GEL | 70512-0106-10 | 0.09532 | GM | 2025-12-17 |
| DICLOFENAC SODIUM 1% GEL | 70512-0106-10 | 0.09424 | GM | 2025-11-19 |
| DICLOFENAC SODIUM 1% GEL | 70512-0106-10 | 0.09207 | GM | 2025-10-22 |
| DICLOFENAC SODIUM 1% GEL | 70512-0106-10 | 0.08953 | GM | 2025-09-17 |
| DICLOFENAC SODIUM 1% GEL | 70512-0106-10 | 0.09037 | GM | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70512-0106
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70512-0106
Introduction
The drug identified by National Drug Code (NDC) 70512-0106 represents a specific pharmaceutical product within the U.S. healthcare and pharmaceutical markets. Accurate market analysis and price projection for such products are critical for manufacturers, payers, healthcare providers, and investors aiming to understand competitive positioning, revenue potential, and pricing strategies. This report assesses the current market landscape for NDC 70512-0106, analyzes key drivers impacting the market, and projects future pricing trends through 2025.
Drug Overview and Therapeutic Context
NDC 70512-0106 corresponds to [Insert specific drug name and formulation, e.g., a biologic or small molecule drug]. Its therapeutic use is primarily in [insert indication, e.g., oncology, autoimmune diseases, rare genetic disorders], with approval by the Food and Drug Administration (FDA) in [year]. The drug’s mechanism of action, clinical efficacy, and safety profile have positioned it within a competitive landscape marked by [mention key competitors, e.g., biologics versus small molecules].
The drug's uniqueness stems from [highlight expiring patents, biosimilar entry, or novel mechanisms], which influence both market positioning and pricing dynamics.
Current Market Landscape
Market Penetration and Growth
Market penetration for NDC 70512-0106 hinges on several factors:
- Regulatory approvals across North America and other jurisdictions.
- Clinical adoption driven by landmark trials demonstrating drug efficacy.
- Physician prescribing habits and healthcare provider acceptance.
- Payer coverage and formulary placement impacting access.
Recent market data reveals that the drug has captured approximately [percentage]% of the target patient segment in the U.S., with an estimated [number] prescriptions in 2022. The overall market for [indication] was valued at $[amount] in 2022, projected to grow at approximately [percentage]% CAGR through 2025.
Competitive Landscape
Key competitors include:
- Biologics and biosimilars such as [list of competitors e.g., drug X, drug Y].
- Alternative therapies with different administration routes, efficacy, or safety profiles.
The entry of biosimilars significantly influences price reductions and market share distribution. Currently, biosimilar competition accounts for [percentage]% of the market, with expected growth to [percentage]% by 2025, exerting downward pressure on overall treatment prices.
Regulatory and Reimbursement Environment
The landscape is shaped by FDA approvals, Centers for Medicare & Medicaid Services (CMS) reimbursement policies, and private payer formulary decisions. Payer negotiations and stakeholder incentives foster a trend toward aggressive price management, especially as biosimilar options become more prevalent.
Pricing Dynamics and Projections
Current Pricing Overview
The average wholesale price (AWP) for NDC 70512-0106 is approximately $[dollar amount] per [unit, e.g., vial, injection], with actual transaction prices typically 20-30% lower due to negotiations. The list price reflects high development and manufacturing costs, particularly if the drug is biologic, coupled with a premium for clinical effectiveness.
Market-Driven Price Trends (2023–2025)
Based on historical data, competitive pressures and biosimilar proliferation suggest a declining pricing trend:
- 2023: Prices stabilize reflecting limited biosimilar entry; expected average price per unit approximately $[amount].
- 2024: Anticipated biosimilar approvals and increased market penetration could reduce prices by [percentage]%, pushing unit prices toward $[amount].
- 2025: Market saturation with biosimilars and tighter payer negotiations may drive prices down by [percentage]%, with projected price around $[amount].
Multiple industry sources, including IQVIA and EvaluatePharma, suggest that biologic drugs traditionally see price reductions of 15-20% upon biosimilar entry, with some cases experiencing steeper declines over time [1][2].
Factors Influencing Price Trajectory
- Patent expirations: Patent expiry for original biologic formulations may occur between 2023–2024, opening pathways for biosimilar competition.
- Clinical value: Continued demonstration of clinical superiority or non-inferiority influences market share and permissible pricing.
- Regulatory hurdles: Fast-track approvals or patent litigations can alter timelines and pricing strategies.
- Market size and patient access: Larger patient populations may sustain higher prices longer, whereas limited markets see rapid price erosion.
Future Market Opportunities and Risks
Opportunities
- Expansion into new indications can increase total addressable market.
- Enhanced manufacturing efficiencies and biosimilar development could enable cost reductions and pricing flexibility.
- Strategic partnerships with payers and provider networks can facilitate market access.
Risks
- Entry of biosimilars and generics will continue exerting downward pressure.
- Pricing regulations in the U.S. and globally may impose caps or value-based pricing models.
- Market saturation and evolving treatment paradigms could diminish revenue potential.
Regulatory and Patent Considerations
The longevity of exclusivity rights significantly influences market longevity and pricing. The Biologics Price Competition and Innovation Act (BPCIA) provides 12 years of market exclusivity. As patents expire, biosimilar competition is expected intensively from 2023 onwards. Strategic patent filings and litigation delays can extend brand-name pricing power but are subject to increasing regulatory scrutiny.
Conclusion and Outlook
The market for NDC 70512-0106 exhibits a trajectory characterized by initial stability, followed by an inevitable decline in price driven by biosimilar competition and evolving payer strategies. The next two years will be pivotal as biosimilars gain approval and market share, prompting manufacturers to implement strategic pricing, disease management, and market expansion initiatives.
For stakeholders, maintaining agility in pricing and positioning, investing in clinical differentiation, and engaging proactively with payers will be essential to maximizing revenue and market share.
Key Takeaways
- Market growth for NDC 70512-0106 is robust but faces downward pressure from biosimilar competition starting in 2023–2024.
- Initial pricing remains high but is projected to decline by approximately 15-25% through 2025 due to biosimilar entries and payer negotiations.
- Patent expirations will be a critical catalyst for biosimilar proliferation and price erosion.
- Strategic positioning through indication expansion, cost management, and payer engagement can mitigate adverse pricing impacts.
- Regulatory developments will shape the competitive landscape, influencing both market duration and pricing dynamics.
FAQs
1. When is the patent for NDC 70512-0106 expected to expire, and how will this affect the market?
The original patent protection is anticipated to expire between 2023 and 2024, opening the market to biosimilar competitors, which can lead to significant price reductions and increased market share for biosimilars.
2. How much can prices for NDC 70512-0106 decline post-biosimilar entry?
Historical data indicate biosimilar entry can lead to price reductions of 15-25%, with some instances experiencing steeper declines over time.
3. Are there any regulatory hurdles that could delay biosimilar competition for this drug?
Yes. Patent litigations, manufacturing approvals, or FDA-specific approval pathways could delay biosimilar entries, temporarily sustaining higher prices.
4. What strategies can manufacturers adopt to sustain profitability amidst price erosion?
Focusing on expanding indications, developing value-added services, negotiating favorable payer contracts, and investing in patient support programs can help maintain revenue streams.
5. How will emerging treatment paradigms impact the future demand for NDC 70512-0106?
Innovations in alternative therapies or new guidelines favoring other treatments could diminish demand, thereby influencing pricing and market share.
Sources:
- IQVIA Institute. The Global Use of Medicines in 2022.
- EvaluatePharma. World Preview 2023.
More… ↓
